CytoDyn’s Phase 3 Trial Demonstrates Safety, a 24% Reduction in Mortality and Faster Hospital Discharge for Mechanically Ventilated Critically Ill COVID-19 Patients Treated with Leronlimab – #stocks chatter

0
289

CytoDyn’s Phase 3 Trial Demonstrates Safety, a 24% Reduction in Mortality and Faster Hospital Discharge for Mechanically Ventilated Critically Ill COVID-19 Patients Treated with Leronlimab

https://www.cytodyn.com/newsroom/press-releases/detail/501/cytodyns-phase-3-trial-demonstrates-safety-a-24

LEAVE A REPLY

Please enter your comment!
Please enter your name here

eighteen − eight =

Leave the field below empty!

This site uses Akismet to reduce spam. Learn how your comment data is processed.